Given that dysregulation of the PERK/eIF2α pathways likely represents a common crucial pathological feature in neurodegenerative diseases [9] and has been well linked to cognitive impairments (as discussed above), determining whether GSK2606414 is effective in other disease models such as AD, PD, or HD is important. This evidence concerns the gene EIF2A and neurodegenerative disease.